+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sucraid Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • PDF Icon

    Report

  • 175 Pages
  • April 2025
  • Region: Global
  • The Business Research Company
  • ID: 6104055
The sucraid market research report is one of a series of new reports that provides sucraid market statistics, including sucraid industry global market size, regional shares, competitors with a sucraid market share, detailed sucraid market segments, market trends and opportunities, and any further data you may need to thrive in the sucraid industry. This sucraid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to telemedicine growth, supportive patient assistance programs, collaborations and partnerships, policy changes favoring rare diseases and focused clinical trials. Major trends in the forecast period include growth in recombinant enzyme production, advancements in oral biologic, expansion of synthetic biology, gene therapy integration, and development of biobetters.

The growth of the sucraid market is anticipated to be driven by the rising prevalence of rare genetic disorders. These conditions, caused by mutations or changes in an individual’s DNA, occur infrequently within the general population. The increasing recognition of genetic disorders can be attributed to advancements in genetic testing, improved detection methods, environmental factors, and certain lifestyle influences that may contribute to DNA mutations. Sucraid plays a critical role by providing enzyme replacement therapy to individuals with congenital sucrase-isomaltase deficiency (CSID), a rare genetic disorder. This therapy helps people digest sucrose and maltose, which are typically indigestible due to a deficiency in the sucrase-isomaltase enzyme. A report from the Cystic Fibrosis Trust in September 2023 highlighted that the number of people in the UK registered with cystic fibrosis surpassed 11,000 in 2022, marking a 5% increase from the previous year. This surge in the number of genetic disorder cases is expected to fuel the demand for sucraid.

The factor contributing to the expansion of the sucraid market is the increase in healthcare expenditure. Healthcare expenditure refers to the total spending on healthcare services and products over a defined period, often measured annually. Rising healthcare costs are driven by factors such as an aging population, the growing prevalence of chronic diseases, technological advancements in medicine, the increasing price of pharmaceuticals, and broader access to healthcare services. Sucraid, as an effective enzyme replacement therapy for CSID, helps reduce overall healthcare spending by preventing costly hospitalizations, diagnostic procedures, and complications arising from untreated digestive disorders. For instance, a report from the Centers for Medicare & Medicaid Services in December 2023 revealed that U.S. healthcare spending increased by 4.1% in 2022, reaching a total of $4.5 trillion, a faster growth rate compared to 3.2% in 2021. As healthcare spending continues to rise, the sucraid market is poised for growth.

The sucraid market is also experiencing growth due to regulatory approvals that expand treatment options and improve access. These approvals, granted by government or regulatory bodies, allow a drug, medical device, or treatment to be marketed for public use. In September 2023, QOL Medical LLC received approval from the U.S. Food and Drug Administration (FDA) for Sucraid (sacrosidase) in single-use containers, specifically designed for patients weighing over 33 pounds (15 kg). This approval addresses previous supply shortages and improves accessibility by providing a dosage form that remains stable at room temperature for up to three days. Such regulatory advancements not only restore the supply of sucraid but also emphasize the importance of innovation in delivering treatments for rare diseases.

The key company operating in the sucraid market is QOL Medical LLC.

North America was the largest region in the sucraid market in 2024. The regions covered in sucraid report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sucraid market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Sucraid is a prescription medication that contains sacrosidase, an enzyme that aids in the breakdown of sucrose (table sugar) into glucose and fructose. It is primarily used to treat congenital sucrase-isomaltase deficiency (CSID), a rare genetic disorder that impairs the body's ability to digest sucrose and other sugars.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for Sucraid include congenital sucrase-isomaltase deficiency (CSID), chronic diarrhea associated with CSID, and gastrointestinal symptoms that may suggest CSID. It is distributed through hospitals and pharmacies, serving a range of end users, including both pediatric and adult patients.

The sucraid market consists of sales of sucraid enzyme supplements, syrups and tablets, and pharmaceuticals for digestive health. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Sucraid Market Characteristics
3. Sucraid Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Sucraid Market Trends And Strategies5. Sucraid Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
6. Global Sucraid Growth Analysis And Strategic Analysis Framework
6.1. Global Sucraid PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Sucraid Market Growth Rate Analysis
6.4. Global Sucraid Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
6.5. Global Sucraid Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
6.6. Global Sucraid Total Addressable Market (TAM)
7. Global Sucraid Pricing Analysis & Forecasts
8. Sucraid Market Segmentation
8.1. Global Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Congenital Sucrase-Isomaltase Deficiency (CSID)
  • Chronic Diarrhea Associated with CSID
  • Unexplained Gastrointestinal Symptoms (Suspected CSID)
8.2. Global Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Hospitals
  • Pharmacies
8.3. Global Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Pediatric
  • Adult
9. Global Sucraid Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Sucraid Market Regional And Country Analysis
10.1. Global Sucraid Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Sucraid Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11. Asia-Pacific Sucraid Market
11.1. Asia-Pacific Sucraid Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.3. Asia-Pacific Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.4. Asia-Pacific Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
12. China Sucraid Market
12.1. China Sucraid Market Overview
12.2. China Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.3. China Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.4. China Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
13. India Sucraid Market
13.1. India Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.2. India Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.3. India Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14. Japan Sucraid Market
14.1. Japan Sucraid Market Overview
14.2. Japan Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.3. Japan Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.4. Japan Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15. Australia Sucraid Market
15.1. Australia Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.2. Australia Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.3. Australia Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16. South Korea Sucraid Market
16.1. South Korea Sucraid Market Overview
16.2. South Korea Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.3. South Korea Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.4. South Korea Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17. Western Europe Sucraid Market
17.1. Western Europe Sucraid Market Overview
17.2. Western Europe Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.3. Western Europe Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.4. Western Europe Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18. UK Sucraid Market
18.1. UK Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.2. UK Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.3. UK Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19. Germany Sucraid Market
19.1. Germany Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.2. Germany Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.3. Germany Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20. France Sucraid Market
20.1. France Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.2. France Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.3. France Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21. Eastern Europe Sucraid Market
21.1. Eastern Europe Sucraid Market Overview
21.2. Eastern Europe Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.3. Eastern Europe Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.4. Eastern Europe Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22. North America Sucraid Market
22.1. North America Sucraid Market Overview
22.2. North America Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.3. North America Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.4. North America Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23. USA Sucraid Market
23.1. USA Sucraid Market Overview
23.2. USA Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.3. USA Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.4. USA Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24. Canada Sucraid Market
24.1. Canada Sucraid Market Overview
24.2. Canada Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.3. Canada Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.4. Canada Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25. South America Sucraid Market
25.1. South America Sucraid Market Overview
25.2. South America Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.3. South America Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.4. South America Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26. Middle East Sucraid Market
26.1. Middle East Sucraid Market Overview
26.2. Middle East Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.3. Middle East Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.4. Middle East Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27. Africa Sucraid Market
27.1. Africa Sucraid Market Overview
27.2. Africa Sucraid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.3. Africa Sucraid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.4. Africa Sucraid Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
28. Sucraid Market Competitive Landscape And Company Profiles
28.1. Sucraid Market Competitive Landscape
28.2. Sucraid Market Company Profiles
28.2.1. QOL Medical LLC Overview, Products and Services, Strategy and Financial Analysis
29. Global Sucraid Market Pipeline Analysis
29.1. High Level Clinic Trail Information
30. Global Sucraid Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Sucraid Market32. Recent Developments In The Sucraid Market
33. Sucraid Market High Potential Countries, Segments and Strategies
33.1 Sucraid Market In 2029 - Countries Offering Most New Opportunities
33.2 Sucraid Market In 2029 - Segments Offering Most New Opportunities
33.3 Sucraid Market In 2029 - Growth Strategies
33.3.1 Market Trend Based Strategies
33.3.2 Competitor Strategies
34. Appendix
34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. About the Analyst
34.6. Copyright And Disclaimer

Executive Summary

Sucraid Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sucraid market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for sucraid ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sucraid market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Clinical Indication: Congenital Sucrase-Isomaltase Deficiency (CSID); Chronic Diarrhea Associated With CSID; Unexplained Gastrointestinal Symptoms (Suspected CSID)
2) By Distribution Channel: Hospitals; Pharmacies
3) By End User: Pediatric; Adult

Key Companies Profiled: QOL Medical LLC

Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • QOL Medical LLC